Key features and details
- Rabbit monoclonal [SP18] to CD79a
- Suitable for: Flow Cyt, IHC-P
- Reacts with: Human
- Isotype: IgG
Product nameAnti-CD79a antibody [SP18]
See all CD79a primary antibodies
DescriptionRabbit monoclonal [SP18] to CD79a
Specificityab16698 recognises CD79a. We have data to indicate that this antibody may not cross react with Opossum. However, this has not been conclusively tested and expression levels may vary in certain cell lines/tissues.
Tested applicationsSuitable for: Flow Cyt, IHC-Pmore details
Species reactivityReacts with: Human
Predicted to work with: Rat, Rabbit, Horse, Chicken, Guinea pig, Cow, Dog, Pig, Monkey
Synthetic peptide within Human CD79a aa 200 to the C-terminus (N terminal). The exact sequence is proprietary.
Database link: P11912
Epitopeab16698 reacts with an epitope located in the N terminal region of CD79a.
- Human tonsil and B cell lymphoma
This product is FOR RESEARCH USE ONLY. For commercial use, please contact email@example.com.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.
Storage bufferpH: 7.50
Preservative: 0.1% Sodium azide
Constituents: Tissue culture supernatant, Tris buffered saline, 1% BSA
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab16698 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use at an assay dependent concentration.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
|IHC-P||1/100. Perform heat mediated antigen retrieval before commencing with IHC staining protocol.|
FunctionRequired in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Stimulates SYK autophosphorylation and activation. Binds to BLNK, bringing BLNK into proximity with SYK and allowing SYK to phosphorylate BLNK. Also interacts with and increases activity of some Src-family tyrosine kinases. Represses BCR signaling during development of immature B cells.
Involvement in diseaseDefects in CD79A are the cause of agammaglobulinemia type 3 (AGM3) [MIM:613501]. It is a primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. Note=Two different mutations, one at the splice donor site of intron 2 and the other at the splice acceptor site for exon 3, have been identified. Both mutations give rise to a truncated protein.
Sequence similaritiesContains 1 Ig-like C2-type (immunoglobulin-like) domain.
Contains 1 ITAM domain.
modificationsPhosphorylated on tyrosine, serine and threonine residues upon B-cell activation. Phosphorylation of tyrosine residues by Src-family kinases is an early and essential feature of the BCR signaling cascade. The phosphorylated tyrosines serve as docking sites for SH2-domain containing kinases, leading to their activation which in turn leads to phosphorylation of downstream targets. Phosphorylation of serine and threonine residues may prevent subsequent tyrosine phosphorylation.
Cellular localizationCell membrane. Following antigen binding, the BCR has been shown to translocate from detergent-soluble regions of the cell membrane to lipid rafts although signal transduction through the complex can also occur outside lipid rafts.
- Information by UniProt
- B lymphocyte-specific MB1 protein antibody
- B-cell antigen receptor complex-associated protein alpha chain antibody
- CD 79a antibody
ab16698 has been referenced in 1 publication.
- Zhang AW et al. Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. Cell 173:1755-1769.e22 (2018). PubMed: 29754820